How to Monitor Suicidal Ideation During VNS Treatment in TRD
How should clinicians systematically monitor suicidal ideation over time in patients with markedly treatment-resistant major depression receiving adjunctive VNS?
Patients with markedly treatment-resistant major depression often have persistent suicidal ideation, and single time-point impressions can miss clinically important change. This guide applies to longitudinal monitoring during adjunctive VNS treatment, where the study assessed suicidal ideation repeatedly and from both clinician-rated and self-reported perspectives.
-
Collect all three suicidal ideation items at each assessment
At each assessment, obtain the suicide item from MADRS item 10, QIDS-C item 12, and QIDS-SR item 12. The study used these three sources together to capture both blinded clinician ratings and patient self-report, recognizing that some patients may disclose ideation differently across formats.
-
Rescale the MADRS suicide item to match the QIDS items
Convert MADRS item 10 from its 0 to 6 scale into a 0 to 3 scale before combining measures. In the study, 0 stayed 0, scores of 1 to 2 were coded as 1, scores of 3 to 4 were coded as 2, and scores of 5 to 6 were coded as 3.
-
Calculate the composite suicidal ideation score
Sum the rescaled MADRS suicide item and the 2 QIDS suicide items to create a composite suicidal ideation score ranging from 0 to 9. Higher scores indicate greater suicidal ideation.
-
Handle missing component data the same way each time
Treat the composite score as missing if at least 2 of the 3 component scales were not completed at that assessment. If only 1 scale was missing, calculate the mean of the 2 available scores and multiply by 3 to estimate the composite total.
-
Classify baseline ideation severity
Use a composite suicidal ideation score of 0 to 2 to represent no or minimal ideation and a score of 3 or higher to represent meaningful suicidal ideation. This threshold determines whether the patient should be followed for improvement or for possible emergence of clinically meaningful ideation.
-
Define clinically meaningful change from baseline
Interpret a change of 3 or more points on the composite score, upward or downward, as clinically meaningful. The study selected this threshold a priori to approximate a 1-point movement on each of the 3 source scales.
-
Define remission only when both change and low residual ideation are present
For patients who begin with meaningful suicidal ideation, define remission as both a drop of 3 or more composite points from baseline and a current composite score of 2 or lower. Do not label remission based on a low current score alone without the required magnitude of improvement.
-
Monitor repeatedly across months rather than relying on single visits
Track suicidal ideation longitudinally across repeated follow-up visits, as the study evaluated months 3 through 12 after implantation. This approach is especially important because improvement with VNS was gradual and the clearest signal was in sustained improvement over time rather than large differences at isolated visits.
Clinical Considerations
- The composite suicidal ideation score used in the study was novel and had not been validated in other contexts.
- The study findings may not generalize to patients with severe suicidal intent or behavior, who were excluded at baseline.
- This monitoring framework was studied in adults with markedly treatment-resistant, nonpsychotic unipolar major depression receiving adjunctive VNS plus treatment as usual.
Bottom Line
When monitoring suicidal ideation during VNS treatment in markedly treatment-resistant major depression, use repeated longitudinal assessment and interpret change with a structured 0 to 9 composite score, where 3 or more points marks clinically meaningful change.
